par Thomas, François;Awada, Ahmad 
Référence Next Generation Sequencing in Cancer Research, Volume 2: From Basepairs to Bedsides, Springer International Publishing, page (19-38)
Publication Publié, 2015-01
Référence Next Generation Sequencing in Cancer Research, Volume 2: From Basepairs to Bedsides, Springer International Publishing, page (19-38)
Publication Publié, 2015-01
Partie d'ouvrage collectif
| Résumé : | Next-generation sequencing (NGS) has great potential to tailorthe treatment of patients to their cancer genome alterations. Casereports, retrospective analysis of phase I trials, open studiesof targeted therapies in population enriched in particular genotypes, and series of breast and lung cancer patients have shown encouraging clinical outcome for the matchingof drugs to specific molecular alterations.Ongoing clinical trials are testing how NGSof tumors can guide individualization of treatment and whether the integration of the NGS into patient care can translate into superior patient outcome. The use of NGS comes with multiple challenges such as access to tumor material, data interpretation, and adaptation of regulatory frameworks for drugs targeting small population and for complex molecular diagnostics. Analytical validation of sequencing platforms and gene panels, access to multiple therapies addressing new targets and development of blood-based tests will support the expanding role of NGS in drug development and clinical trials. |
